HPV Transcriptome Biomarker for Cancer Stage Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current HPV detection methods are limited in their ability to broadly identify high-risk HPV types and do not effectively distinguish between different HPV genotypes, leading to inadequate cancer diagnosis and management, as they rely on specific oligonucleotides binding to few DNA or transcript types, failing to account for the genetic diversity of HPV and the shift in infection patterns during cancer development.
Innovation Solution
A method utilizing consensus primers for broad amplification of HPV genes, particularly E6 and E7 mRNAs, through High-Throughput sequencing, allowing for the identification of various HPV genotypes and the calculation of ratios between oncogenic and structural genes to assess cancer risk, enabling the detection of HPV-induced cancer risk beyond specific high-risk types.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If specific oligonucleotides are used to detect HPV DNA or transcripts, then detection specificity for certain high-risk HPV types is improved, but the ability to broadly identify diverse HPV genotypes deteriorates
Solution Approach 1:
The patent employs consensus primers that can universally amplify a broad spectrum of HPV genotypes simultaneously. These primers are designed to bind to conserved regions across multiple HPV types, enabling a single assay to detect diverse genotypes rather than requiring separate specific assays for each type, thus achieving multi-functionality in HPV detection
Solution Approach 2:
The patent segments the HPV detection approach by analyzing the transcriptome profile across multiple gene regions (early genes E6, E7, E5 and late genes L1, L2) rather than relying on a single target. This segmentation allows comprehensive genotype identification and risk assessment by evaluating expression patterns across different viral genome regions
2Reliability
If HPV DNA identification is used for cancer screening, then detection of HPV presence is improved, but predictive value for cancer development deteriorates due to low positive predictive value
Solution Approach 1:
The patent changes the detection parameter from static HPV DNA presence to dynamic transcript expression levels. By quantifying mRNA expression levels of oncogenic genes (E6, E7) and comparing them to structural genes (L1, L2), the assay captures the active transcriptional state that correlates with carcinogenic potential, thereby improving cancer prediction accuracy over simple DNA detection
Solution Approach 2:
The patent implements a risk stratification feedback system that uses transcriptome data to categorize patients into different risk groups. The ratio of early to late gene expression serves as a feedback parameter that indicates progression stage and cancer risk, allowing clinicians to adjust screening intensity and management strategies based on the measured transcript levels
3Measurement precision
If E6 and E7 mRNA expression is measured as a cancer marker, then sensitivity for cancer development is improved, but ability to distinguish between infection stages deteriorates due to expression during acute infection
Solution Approach 1:
The patent merges the detection of multiple gene expressions (E6, E7, E5, L1, L2) into a single comprehensive transcriptome profile. By combining information from oncogenic early genes and structural late genes, the assay distinguishes between productive infection (high late gene expression) and non-productive/carcinogenic infection (high early to late gene ratio), thereby maintaining stage differentiation capability while using E6/E7 as cancer markers
Solution Approach 2:
The patent adds a temporal and quantitative dimension to E6/E7 detection by measuring expression levels relative to housekeeping genes and other viral transcripts. Instead of binary presence/absence, the assay evaluates the magnitude of expression and its ratio to late genes, creating a multidimensional marker that distinguishes acute from persistent carcinogenic infection
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach provides a more comprehensive and accurate assessment of HPV-induced cancer risk by identifying relevant biomarkers across a wide range of HPV types, improving diagnostic capabilities and predictive value for cancer development.
Implementation Method 1
enrichment of the viral RNAs in a sample using random or consensus pre-amplification and/or specific reverse transcriptase reaction
Implementation Method 2
amplification of the produced cDNA
Implementation Method 3
sequencing the cDNA; generating reads of sequence of the cDNA; discriminating HPV sequence reads on the basis of HPV specie; discriminating HPV sequence reads on the basis of HPV gene transcript
Data Source
AI summary
The present invention provides compositions, kits, and method for determining the levels of expression of human polyoma or papillomavirus species and RNA transcripts. These levels can be used for the prognosis of risk of developing virally-induced cancers. The ratio (R) between early and late transcripts is indicative of HPV infections associated with higher risk of developing genital neoplasia and cancer.